Clinical Trial Update: A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating efruxifermin in adults with compensated cirrhosis due to NASH/MASH is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• efruxifermin (efruxifermin)

Snippet

Sponsor: Akero Therapeutics, Inc | Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis | Phase 3 | Status: RECRUITING